Literature DB >> 12145324

Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.

Ronald B DeMattos1, Mark A O'dell, Maia Parsadanian, Jennie W Taylor, Judith A K Harmony, Kelly R Bales, Steven M Paul, Bruce J Aronow, David M Holtzman.   

Abstract

Studies have shown that clusterin (also called apolipoprotein J) can influence the structure and toxicity of amyloid-beta (Abeta) in vitro. To determine whether endogenous clusterin plays a role in influencing Abeta deposition, structure, and toxicity in vivo, we bred PDAPP mice, a transgenic mouse model of Alzheimer's disease, to clusterin(-/-) mice. By 12 months of age, PDAPP, clusterin(-/-) mice had similar levels of brain Abeta deposition as did PDAPP, clusterin(+/+) mice. Although Abeta deposition was similar, PDAPP, clusterin(-/-) mice had significantly fewer fibrillar Abeta (amyloid) deposits than PDAPP mice expressing clusterin. In the absence of clusterin, neuritic dystrophy associated with the deposited amyloid was markedly reduced, resulting in a dissociation between fibrillar amyloid formation and neuritic dystrophy. These findings demonstrate that clusterin markedly influences Abeta structure and neuritic toxicity in vivo and is likely to play an important role in Alzheimer's disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145324      PMCID: PMC125060          DOI: 10.1073/pnas.162228299

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

Authors:  W L Klein; G A Krafft; C E Finch
Journal:  Trends Neurosci       Date:  2001-04       Impact factor: 13.837

Review 2.  Alzheimer's disease: perspectives for the new millennium.

Authors:  S S Sisodia
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 3.  Apolipoprotein J (clusterin) and Alzheimer's disease.

Authors:  M Calero; A Rostagno; E Matsubara; B Zlokovic; B Frangione; J Ghiso
Journal:  Microsc Res Tech       Date:  2000-08-15       Impact factor: 2.769

4.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.

Authors:  K R Bales; T Verina; D J Cummins; Y Du; R C Dodel; J Saura; C E Fishman; C A DeLong; P Piccardo; V Petegnief; B Ghetti; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model.

Authors:  D M Holtzman; A M Fagan; B Mackey; T Tenkova; L Sartorius; S M Paul; K Bales; K H Ashe; M C Irizarry; B T Hyman
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

Review 6.  Biology of A beta amyloid in Alzheimer's disease.

Authors:  T Wisniewski; J Ghiso; B Frangione
Journal:  Neurobiol Dis       Date:  1997       Impact factor: 5.996

7.  Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis.

Authors:  L McLaughlin; G Zhu; M Mistry; C Ley-Ebert; W D Stuart; C J Florio; P A Groen; S A Witt; T R Kimball; D P Witte; J A Harmony; B J Aronow
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

8.  Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state.

Authors:  S Poon; S B Easterbrook-Smith; M S Rybchyn; J A Carver; M R Wilson
Journal:  Biochemistry       Date:  2000-12-26       Impact factor: 3.162

9.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.

Authors:  D M Holtzman; K R Bales; T Tenkova; A M Fagan; M Parsadanian; L J Sartorius; B Mackey; J Olney; D McKeel; D Wozniak; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

10.  Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection.

Authors:  B J Aronow; S D Lund; T L Brown; J A Harmony; D P Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

View more
  129 in total

1.  Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer's disease.

Authors:  Anna Lord; Ola Philipson; Therése Klingstedt; Gunilla Westermark; Per Hammarström; K Peter R Nilsson; Lars N G Nilsson
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Molecular diversity of astrocytes with implications for neurological disorders.

Authors:  Robert M Bachoo; Ryung S Kim; Keith L Ligon; Elizabeth A Maher; Cameron Brennan; Nathan Billings; Suzanne Chan; Cheng Li; David H Rowitch; Wing H Wong; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-21       Impact factor: 11.205

3.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 4.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

5.  Predicting white matter integrity from multiple common genetic variants.

Authors:  Omid Kohannim; Neda Jahanshad; Meredith N Braskie; Jason L Stein; Ming-Chang Chiang; April H Reese; Derrek P Hibar; Arthur W Toga; Katie L McMahon; Greig I de Zubicaray; Sarah E Medland; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Paul M Thompson
Journal:  Neuropsychopharmacology       Date:  2012-04-18       Impact factor: 7.853

Review 6.  Challenging Proteostasis: Role of the Chaperone Network to Control Aggregation-Prone Proteins in Human Disease.

Authors:  Tessa Sinnige; Anan Yu; Richard I Morimoto
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  Association between CLU gene rs11136000 polymorphism and Alzheimer's disease: an updated meta-analysis.

Authors:  Ruixia Zhu; Xu Liu; Zhiyi He
Journal:  Neurol Sci       Date:  2018-02-02       Impact factor: 3.307

8.  Clusterin associates with altered elastic fibers in human photoaged skin and prevents elastin from ultraviolet-induced aggregation in vitro.

Authors:  Elke Janig; Martin Haslbeck; Ariane Aigelsreiter; Nathalie Braun; Daniela Unterthor; Peter Wolf; Noor M Khaskhely; Johannes Buchner; Helmut Denk; Kurt Zatloukal
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

9.  Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.

Authors:  Jungsu Kim; Joseph M Castellano; Hong Jiang; Jacob M Basak; Maia Parsadanian; Vi Pham; Stephanie M Mason; Steven M Paul; David M Holtzman
Journal:  Neuron       Date:  2009-12-10       Impact factor: 17.173

10.  Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Authors:  Robert D Bell; Abhay P Sagare; Alan E Friedman; Gurrinder S Bedi; David M Holtzman; Rashid Deane; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2006-11-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.